Drugs / AZD5069
Trials 15
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT01890148 | Mar → Aug 2014 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01989520 | Jan → Apr 2014 | chronic asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01735240 | Dec 2012 → Feb 2013 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01480739 | Dec 2011 → Jul 2012 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01332903 | May → Jul 2011 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01100047 | May 2010 → Feb 2011 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01083238 | Feb → Jul 2010 | chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01051505 | Jan → Apr 2010 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00953888 | Jul → Dec 2009 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT03177187 | Nov 2017 → Sep 2022 | castration-resistant prostate carcinoma | Institute of Cancer Research, United Kingdom | Terminated | No outcome recorded |
| Phase 1/2 | NCT02583477 | Mar 2016 → Jul 2018 | pancreatic ductal adenocarcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 1/2 | NCT02499328 | Aug 2015 → Feb 2020 | head and neck squamous cell carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 23 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT01704495 | Nov 2012 → Aug 2014 | asthma | AstraZeneca | Completed | Missed primary |
| Phase 2 | NCT01255592 | Feb 2011 → Feb 2012 | bronchiectasis | AstraZeneca | Completed | Met primary |
| Phase 2 | NCT01233232 | Nov 2010 → Mar 2011 | chronic bronchitis | AstraZeneca | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01962935 Comparator | Nov 2013 → Jun 2014 | chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD5069 | “received single (0.1-200 mg) or multiple once- or twice-daily (10-120 mg) oral AZD5069 as solution, suspension, capsules or tablets.” PMID 29856004 ↗ Jun 2018 |
| Action | Inhibit | “a selective small-molecule CXCR2 antagonist” PMID 29856004 ↗ Jun 2018 |
| Modality | Small molecule | “a selective small-molecule CXCR2 antagonist” PMID 29856004 ↗ Jun 2018 |
| Route | Oral | “healthy volunteers given oral AZD5069” PMID 29856004 ↗ Jun 2018 |
| Target | CXCR2 | “a selective small-molecule CXCR2 antagonist” PMID 29856004 ↗ Jun 2018 |